Here it is, ladies and gentlemen. Today we’re heading downhill — $SPGI cut its outlook, even though the numbers beat expectations, and the stock is already feeling it; of course it’s being followed by $MSCI and others.
So what exactly were SPGI’s results and is the stock’s decline justified? We’re reaching unprecedented levels.
This week brings results from several key positions in my portfolio. Here is an overview with my take on each, supported by a rationale.
$KO : I expect a standard report with minimal surprises; in turbulent times this is a stock that holds its value and serves as a safer haven. Rationale: Consensus estimates Q4 2025 EPS $0.57 (+3.6... Read more
I see that shares of $HIMS have fallen more than 60% from their all-time highs (ATH), which is no small amount. I personally don't follow this company closely right now, but I'd be interested to know the main reasons for this decline.
Does anyone have any idea why $HIMS shares have dropped so significantly? Do you see it more as an opportunity or as a trap?
I own some and I'm considering buying more. They have excellent results, the market is large, and they've even started international expansion in telehealth. The market may be wondering whether that rapid growth is sustainable. And in the US everyone is probably nervous about Trump's interference in this segment. They'll likely be sparring again with the big US market player, company $NVO, over the weight-loss drug they devised themselves, with Wegovy as their benchmark. It probably isn't for someone who doesn't like big swings, but their business model is hard to deny.
Bulios Black
This user has access to exclusive content, tools and features of the Bulios platform thanks to their subscription.
Coca-Cola grows steadily, but margins face a real stress test
Bulios Black
This user has access to exclusive content, tools and features of the Bulios platform thanks to their subscription.
Down 22% in a month: a real opportunity if SoFi executes in 2026
Bulios Black
This user has access to exclusive content, tools and features of the Bulios platform thanks to their subscription.
Here it is, ladies and gentlemen. Today we’re heading downhill — $SPGI cut its outlook, even though the numbers beat expectations, and the stock is already feeling it; of course it’s being followed by $MSCI and others.
So what exactly were SPGI’s results and is the stock’s decline justified? We’re reaching unprecedented levels.
Thanks
Zobrazit další komentáře
Today I'll probably start dollar-cost averaging (DCA) into this company gradually.
Bulios Black
This user has access to exclusive content, tools and features of the Bulios platform thanks to their subscription.
Software’s Historic Sell-Off: Is the Worst Already Priced In?
SpaceX wants to build a base on the Moon. And the market is already thinking about only one thing: When will the IPO happen?
Read more
Zobrazit další komentáře
I've read a bit about it too, and the IPO will probably happen eventually, but it will take some time.
SpaceX wants to build a base on the Moon. And the market is already thinking about only one thing: When will the IPO come?
Read more
Zobrazit další komentáře
Bulios Black
This user has access to exclusive content, tools and features of the Bulios platform thanks to their subscription.
I've read a bit about it too, and the IPO will probably happen eventually, but it'll take some time.
Bulios Black
This user has access to exclusive content, tools and features of the Bulios platform thanks to their subscription.
AT&T delivers steady cash flow, but lacks a clear growth catalyst
Bulios Black
This user has access to exclusive content, tools and features of the Bulios platform thanks to their subscription.
Oracle Rallies as AI Cloud Demand and Strategic Growth Catalysts Drive Gains
Bulios Black
This user has access to exclusive content, tools and features of the Bulios platform thanks to their subscription.
UnitedHealth posts record revenue, but cost pressure clouds the outlook
Bulios Black
This user has access to exclusive content, tools and features of the Bulios platform thanks to their subscription.
$4 billion in orders and satellites about to go live: execution finally takes center stage
Results from companies in my portfolio this week
This week brings results from several key positions in my portfolio. Here is an overview with my take on each, supported by a rationale.
$KO : I expect a standard report with minimal surprises; in turbulent times this is a stock that holds its value and serves as a safer haven. Rationale: Consensus estimates Q4 2025 EPS $0.57 (+3.6...
Read more
Zobrazit další komentáře
I'll be very interested in inflation, because it can change a lot of things again.
Bulios Black
This user has access to exclusive content, tools and features of the Bulios platform thanks to their subscription.
The Most Distressed Stocks in the DAX in 2026
Bulios Black
This user has access to exclusive content, tools and features of the Bulios platform thanks to their subscription.
Boeing returns to profit, but the recovery remains fragile
Bulios Black
This user has access to exclusive content, tools and features of the Bulios platform thanks to their subscription.
Fiserv’s Upcoming Earnings Report Is a Litmus Test for Investor Confidence
I see that shares of $HIMS have fallen more than 60% from their all-time highs (ATH), which is no small amount. I personally don't follow this company closely right now, but I'd be interested to know the main reasons for this decline.
Does anyone have any idea why $HIMS shares have dropped so significantly? Do you see it more as an opportunity or as a trap?
Zobrazit další komentáře
I own some and I'm considering buying more. They have excellent results, the market is large, and they've even started international expansion in telehealth. The market may be wondering whether that rapid growth is sustainable. And in the US everyone is probably nervous about Trump's interference in this segment. They'll likely be sparring again with the big US market player, company $NVO, over the weight-loss drug they devised themselves, with Wegovy as their benchmark. It probably isn't for someone who doesn't like big swings, but their business model is hard to deny.